Global Intravenous Immunoglobulin Market

Global Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP), By Type(IgG, IgM), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy) - Industry Forecast 2024-2031


Report ID: SQMIG35A2611 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 100 | Figures: 69

Global Intravenous Immunoglobulin Market Insights

Global Intravenous Immunoglobulin Market size was valued at USD 11.98 billion in 2022 and is poised to grow from USD 12.9 billion in 2023 to USD 22.6 billion by 2031, growing at a CAGR of 7.3% in the forecast period (2024-2031).

The market for intravenous immunoglobulin (IVIG) is propelled by several key drivers, including the burgeoning geriatric population, a surge in immunodeficiency diseases, wider adoption of IVIG treatments, and the expanding use of off-label indications. The escalating prevalence of patients grappling with immunodeficiency disorders remains a primary catalyst behind the development and demand for IVIG preparations.

This global market is experiencing rapid expansion, attributed to a growing number of patients contending with bleeding issues and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The increased investments in the healthcare sector further support the growth of the IVIG market.

Moreover, the mounting incidence of autoimmune illnesses and various pathological conditions contributes significantly to the expanding market landscape for IVIG products, underscoring their pivotal role in addressing diverse medical needs.

Market snapshot - 2024-2031

Global Market Size

USD 11.98 billion

Largest Segment

Specialty Pharmacy

Growth Rate

7.3% CAGR

Global Intravenous Immunoglobulin Market By Distribution Channel ($ Bn)
Country Share for North America Region (%)
Global Intravenous Immunoglobulin Market By Distribution Channel (%)

To get more reports on the above market click here to Buy The Report

Global Intravenous Immunoglobulin Market Segmental Analysis

The global Intravenous Immunoglobulin market is segmented into four segments i.e. by Application, Type, Distribution Channel, and Region. Based on Application the market is segmented as, Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome, Others. Based on Type the market is segmented as, IgG, IgM, IgA, IgE, IgD. Based on Distribution Channel the market is segmented as, Hospital Pharmacy, Specialty Pharmacy, Others. Based on Regional the market is segmented as, North America, Asia Pacific, Latin America.

Analysis by Application

In 2022, immunodeficiency diseases emerged as a dominant force in the market, commanding a substantial revenue share exceeding 20.30%. This dominance is attributable to the escalating incidence of both primary and acquired immunodeficiency diseases (PID & AID). Treating PID & AID often requires IV antibiotics to combat infections, with IVIG replacement therapy standing out as the premier alternative for managing these conditions. Consequently, the sector is poised for steady growth in the foreseeable future.

The chronic inflammatory demyelinating polyneuropathy (CIDP) segment secured the second-largest share in the IVIG market based on its application. Commonly identified in patients with diabetes mellitus, CIDP treatment typically involves the utilization of immunosuppressive drugs, steroids, and plasmapheresis. IVIG stands out as a highly effective and enduring alternative to these conventional methods. Its adoption is bolstered by associated benefits such as safety, minimally invasive administration, and user-friendly treatment options.

Analysis by Distribution Channel

The forecast period anticipates significant growth within the specialty pharmacy segment, primarily due to the inherent advantages they offer in facilitating convenient home-based treatments. Specialty pharmacies play a pivotal role in this trajectory, providing ease of access and administration for specialized medications at patients' homes. As the landscape of pharmacy business evolves, specialty drugs have emerged as a crucial and dynamic sector.

In 2022, the hospital pharmacy segment established its dominance within the market, securing a substantial revenue share exceeding 57.83%. This prevalence stems from the widespread reach of hospitals housing these pharmacies, providing convenient access to a diverse array of pharmaceutical products. Moreover, the global upsurge in hospitalizations due to conditions like primary immune deficiencies, hepatitis C, and several other diseases has notably influenced consumer behavior.

Global Intravenous Immunoglobulin Market By Distribution Channel , 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Global Intravenous Immunoglobulin Market Regional Insights

In 2022, North America emerged as the leading force within the market, securing a commanding revenue share of 46.51%. The region's dominance stems from several pivotal factors fostering its market growth. Notably, there has been a substantial uptick in awareness regarding products designed to address immunodeficiency diseases, fostering a deeper understanding among both healthcare professionals and the general populace.

Asia Pacific is positioned for remarkable growth, propelled by a convergence of key factors. Heightened awareness and increasing opportunities surrounding the adoption of immunoglobulin-based therapies for addressing primary immune deficiencies serve as primary catalysts for this growth. The expanding geriatric demographic within the region also emerges as a pivotal factor contributing to this upward trajectory, amplifying the demand for specialized therapies. Moreover, the region's emerging economies, coupled with increasing healthcare expenditures, further bolster the sector's development.

Global Intravenous Immunoglobulin Market By Region, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Intravenous Immunoglobulin Market Dynamics

Drivers

Increasing Adoption of Intravenous Immunoglobulins to Drive Market Growth

  • The pervasive uptake of intravenous immunoglobulin therapy as the foremost treatment avenue for numerous rare immunological and neurological conditions, notably primary immunodeficiency (PI) and associated diseases, emerges as a cornerstone propelling the expansion of the intravenous immunoglobulin market. This extensive acceptance of IVIG therapy as the frontline treatment signifies its efficacy and relevance in managing these conditions effectively.

Restraints

High Cost of Treatment to Impede Market Growth

  • The diagnosis and treatment expenses associated with demyelinating diseases present a considerable financial burden. The rising costs linked to IVIG therapy stand out as a significant barrier to the market's expansion. Typically administered every 3 to 4 weeks, IVIG infusions are recurrent, involving approximately 12 to 16 sessions annually. The projected cost of IVIG is estimated at USD 73.89 per gram, amounting to a total expense of around USD 10,000.

Request Free Customization of this report to help us to meet your business objectives.

Global Intravenous Immunoglobulin Market Competitive Landscape

The competitive environment of the global Intravenous Immunoglobulin Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.

Top Player’s Company Profiles

  • Grifols SA
  • Octapharma AG
  • ADMA Biologics
  • LFB Biotechnologies
  • Kedrion Biopharma,
  • Intas Pharmaceuticals.
  • Biotest AG
  • BDI Pharma Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited.
  • CSL Behring
  • Baxter International Inc.
  • China Biologics Products Inc.

Recent Developments

  • In January 2024, the US Food & Drug Administration (FDA) has approved Takeda’s HYQVIA (immune globulin infusion (human) 10% solution) to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). According to a company press release, HYQVIA is the only FDA-approved combination of IG and hyaluronidase, making it a facilitated subcutaneous IG (SCIG) infusion.

     

  • In July 2023, GC Biopharma has announced that it has signed a deal with Blau Farmaceutica, a Brazilian partner, to supply its immunoglobulin blood product, Immune Globulin Intravenous (IVIG-SN5%), to Brazil until 2028. The GC Biopharma blood products are at an estimated cost of $90.48 million. Brazil is the largest market for blood products in South America, with an estimated market size of $270 million for immunoglobulins as of 2022.

     

  • In June 2023, Drug Administration of Vietnam under the Ministry of Health (MoH) had imported 6,000 bottles of Plasma-derived Intravenous Immunoglobulin (IVIG) to Vietnam to supply local hospitals for treatment of hand, foot and mouth disease (HFMD). According to details given by the MoH, the quantity of drugs met the urgent needs of hospitals. However, due to sharp increases in infection numbers, the MoH requested that importers move to ensure IVIG drug supply in a bid to meet the increasing demand of the hospitals.

Global Intravenous Immunoglobulin Key Market Trends

  • The market's evolution is being driven by several impactful trends that are reshaping its trajectory for growth and progress. Notably, the rising use of Intravenous Immunoglobulin (IVIG) in treating neurological disorders marks a significant trend, highlighting its expanding application beyond traditional uses. Additionally, the integration of personalized medicine principles into IVIG therapy represents a notable shift, tailoring treatments to individual patient needs. The emergence of novel immunomodulatory treatments is also shaping the landscape, offering innovative therapeutic avenues.

Global Intravenous Immunoglobulin Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

The global Intravenous Immunoglobulin market analysis reveals a dynamic marketplace with a number of standout trends and difficulties. The market for Intravenous Immunoglobulin (IVIG) is principally steered by several key factors. Among these are the expanding elderly population demographic, the rising incidence of immunodeficiency disorders, increased adoption of IVIG treatments, and the growing utilization of off-label indications. IVIG preparations have notably evolved in response to the escalating number of patients afflicted by immunodeficiency disorders. This surge in demand and the expanding spectrum of applications for IVIG underscore its critical role in addressing various medical conditions and the growing need for therapeutic solutions in diverse patient populations.

Report Metric Details
Market size value in 2023 USD 11.98 billion
Market size value in 2031 USD 22.6 billion
Growth Rate 7.3%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Application
    • Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome, and Others
  • Type
    • IgG, IgM, IgA, IgE, and IgD
  • Distribution Channel
    • Hospital Pharmacy, Specialty Pharmacy, and Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Grifols SA
  • Octapharma AG
  • ADMA Biologics
  • LFB Biotechnologies
  • Kedrion Biopharma,
  • Intas Pharmaceuticals.
  • Biotest AG
  • BDI Pharma Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited.
  • CSL Behring
  • Baxter International Inc.
  • China Biologics Products Inc.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Intravenous Immunoglobulin Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Intravenous Immunoglobulin Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Intravenous Immunoglobulin Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Intravenous Immunoglobulin Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Intravenous Immunoglobulin Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Intravenous Immunoglobulin Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Intravenous Immunoglobulin Market size was valued at USD 11.98 billion in 2022 and is poised to grow from USD 12.9 billion in 2023 to USD 22.6 billion by 2031, growing at a CAGR of 7.3% in the forecast period (2024-2031).

The competitive environment of the global Intravenous Immunoglobulin Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Grifols SA', 'Octapharma AG', 'ADMA Biologics', 'LFB Biotechnologies', 'Kedrion Biopharma,', 'Intas Pharmaceuticals.', 'Biotest AG', 'BDI Pharma Inc.', 'Shanghai RAAS Blood Products Co., Ltd.', 'Takeda Pharmaceutical Company Limited.', 'CSL Behring', 'Baxter International Inc.', 'China Biologics Products Inc.'

The pervasive uptake of intravenous immunoglobulin therapy as the foremost treatment avenue for numerous rare immunological and neurological conditions, notably primary immunodeficiency (PI) and associated diseases, emerges as a cornerstone propelling the expansion of the intravenous immunoglobulin market. This extensive acceptance of IVIG therapy as the frontline treatment signifies its efficacy and relevance in managing these conditions effectively.

The market's evolution is being driven by several impactful trends that are reshaping its trajectory for growth and progress. Notably, the rising use of Intravenous Immunoglobulin (IVIG) in treating neurological disorders marks a significant trend, highlighting its expanding application beyond traditional uses. Additionally, the integration of personalized medicine principles into IVIG therapy represents a notable shift, tailoring treatments to individual patient needs. The emergence of novel immunomodulatory treatments is also shaping the landscape, offering innovative therapeutic avenues.

In 2022, North America emerged as the leading force within the market, securing a commanding revenue share of 46.51%. The region's dominance stems from several pivotal factors fostering its market growth. Notably, there has been a substantial uptick in awareness regarding products designed to address immunodeficiency diseases, fostering a deeper understanding among both healthcare professionals and the general populace.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Intravenous Immunoglobulin Market

Product ID: SQMIG35A2611

$5,300
BUY NOW GET FREE SAMPLE